Activating a B cell immune response regresses immunologically cold tumours

By afschroeder • June 13, 2026

Aggarwal H, Gupta N, Sengupta A, Sarkar A, Mylavarapu S, Pires IS, Saha T, Sarkar B, Kulkarni A, Mahajan VS, Goyal L, Bardia A, Fahrner R, Gherardi E, Mashelkar R, Soon-Shiong P, Jang HL, Sengupta S. Activating a B cell immune response regresses immunologically cold tumours. Nat Nanotechnol. 2026 Jun 12. doi: 10.1038/s41565-026-02170-9. Epub ahead of print. PMID: 42286216.

Tags: Hematology/Oncology, Publications

Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer

Mouabbi JA, Lipsyc-Sharf MD, Yan F. Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):1-16.[...]

Interpreting MRD results and integrating assays into practice

Lipsyc-Sharf MD. Interpreting MRD results and integrating assays into practice. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):7-11. PMID: 42283708.

Practical approach to MRD testing in breast cancer: Q&A

Mouabbi JA, Lipsyc-Sharf MD, Yan F. Practical approach to MRD testing in breast cancer: Q&A. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):11-15. PMID: 42283709.